Brandon Jones, MD
Interventional Cardiology · Portland, ORNPI 1043447873
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Abbott accounts for 60.1% of it on its own, with 23 other manufacturers making up the rest. 2025 is the largest year on record at $36,004, more than ten times the $884 reported in 2019. Among interventional cardiology clinicians in OR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $382.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$61K
- Medtronic$24K
- W. L. Gore & Associates, Inc.$8K
- Ancora Heart, Inc.$3K
- Edwards Lifesciences$2K
- Boston Scientific$2K
- plus $1K from 18 others
Across 125 payments — averaging $5097.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$370K
- Edwards Lifesciences$155K
- W. L. Gore & Associates, Inc.$69K
- Boston Scientific$43K
What the payments were for
- Consulting fees$45,91045%
- Speaking & faculty fees$5,6756%
- Travel & lodging$39,85439%
- Food & beverage$9,96510%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 96 | $60,990 |
| Medtronic(2 entities) | 57 | $23,806 |
| W. L. Gore & Associates, Inc. | 6 | $7,560 |
| Ancora Heart, Inc. | 23 | $3,464 |
| Edwards Lifesciences | 36 | $2,381 |
| Boston Scientific | 15 | $2,098 |
| Cardiva Medical, Inc. | 1 | $150 |
| Heartflow, Inc. | 1 | $145 |
| Pfizer | 6 | $114 |
| Shockwave Medical, Inc | 6 | $109 |
| Bard Peripheral Vascular, Inc. | 1 | $100 |
| Abiomed | 1 | $90 |
| Neovasc Medical Inc | 1 | $76 |
| Inari Medical, Inc. | 1 | $55 |
| Cardiac Dimensions, Inc. | 2 | $51 |
| Penumbra, Inc. | 3 | $45 |
| A-dec, Inc. | 1 | $41 |
| Philips North America LLC | 1 | $36 |
| Teleflex LLC | 2 | $33 |
| Jenavalve Technology, Inc. | 1 | $28 |
| Terumo Medical Corporation | 1 | $21 |
| Biosense Webster, Inc. | 1 | $20 |
| Cardiovascular Systems Inc. | 1 | $18 |
| Cardinal Health 200 LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NAVITOR$26,360
- COREVALVE EVOLUT R$22,748
- TRICLIP$18,237
- PORTICO$7,668
- GORE CARDIOFORM Septal Occluder$7,560
- MitraClip$4,019
- AccuCinch$3,173
- Perclose ProStyle$868
- SAPIEN 3 Ultra RESILIA$457
- EVOQUE$409
- Mitra Clip system$373
- ESPRIT$151
- SavvyWire$150
- GENERAL - STENTS$146
- GENERAL - STRUCTURAL HEART$144
- APOLLOTM$108
- AMPLATZER TALISMAN$103
- LUTONIX$100
How this compares
$101,444 in reported general payments places this provider in the 90th percentile of 68 interventional cardiology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $13,317 |
| ClopidogrelClopidogrel Bisulfate | 40 | $623 |
| Atorvastatin Calcium | 31 | $490 |
| Metoprolol Succinate | 30 | $305 |
| Rosuvastatin Calcium | 23 | $170 |
| Lisinopril | 16 | $107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $114 | $13,31714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 68 interventional cardiology providers in Oregon.
Other interventional cardiology in Portland
- Jason WollmuthPortland$749K
- Ethan KorngoldPortland$407K
- Amish DesaiPortland$186K
- Harsh GolwalaPortland$105K
- Kathryn DawsonPortland$57K
- Logan VincentPortland$42K
- Amged AbdelazizPortland$38K
- Richard SohnPortland$38K
- Daniel FeldmanPortland$36K
- Kris KumarPortland$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.